TriSalus Life Sciences (TLSI) Invested Capital (2020 - 2026)

TriSalus Life Sciences (TLSI) has 7 years of Invested Capital data on file, last reported at $45.9 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 1817.93% year-over-year to $45.9 million; the trailing twelve-month figure through Mar 2026 stood at $45.9 million (up 1817.93% YoY), and the FY2025 full-year result was -$815000.0, up 78.61% from the prior year.
• Invested Capital for Q1 2026 stood at $45.9 million, up from -$815000.0 in the prior quarter.
• Across five years, Invested Capital topped out at $45.9 million in Q1 2026 and bottomed at -$188.4 million in Q2 2023.
• The 5-year median for Invested Capital is -$4.0 million (2024), against an average of -$57.7 million.
• The widest annual swing landed in 2022, when Invested Capital slumped 684.82%; it then jumped 1817.93% in 2026.
• A 5-year view of Invested Capital shows it stood at -$174.7 million in 2022, then soared by 84.51% to -$27.1 million in 2023, then soared by 85.92% to -$3.8 million in 2024, then jumped by 78.61% to -$815000.0 in 2025, then soared by 5730.18% to $45.9 million in 2026.
• The last three Invested Capital figures came in at $45.9 million (Q1 2026), -$815000.0 (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.

Peer Comparison